<DOC>
	<DOCNO>NCT02336698</DOCNO>
	<brief_summary>The purpose study demonstrate efficacy , safety , tolerability fulranumab Monotherapy compare placebo participant sign symptom osteoarthritis hip knee adequately control current pain therapy .</brief_summary>
	<brief_title>Study Efficacy , Safety Fulranumab Monotherapy OA Hip Knee , PAI3002</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , double-blind ( neither physician participant know name assigned drug ) , placebo-controlled ( inactive substance give one group participant active drug give another group participant see difference response ) , parallel-group ( study drug give participant treatment group time period ) evaluate efficacy ( capacity investigational drug produce effect ) , safety , tolerability fulranumab administer monotherapy ( alone ; combination drug therapy ) participant chronic moderate severe pain functional impairment knee hip osteoarthritis ( OA ) adequately control current pain therapy . The duration participation study individual participant 67 week ( include screen period 3 week , double-blind treatment period 16 week , post-treatment follow-up period 48 week ) . ) . All participant randomly assign 1:1:1 ratio 1 3 treatment ( placebo , fulranumab 1mg , fulranumab 3mg ) give single injection subcutaneously ( skin ) every 4 week 16 week . Blood sample collect participant time point study . Safety evaluation include assessment adverse event , physical examination , laboratory test vital sign monitor throughout study .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Clinical diagnosis osteoarthritis ( OA ) hip knee base criterion define American College Rheumatology radiographic evidence OA ( KellgrenLawrence class â‰¥2 ) study joint Scheduled joint replacement plan undergo joint replacement surgery study joint Must unsatisfactory response ( inadequate efficacy poor tolerability ) include 3 class analgesic medication ( acetaminophen/paracetamol , NSAID , opioid ) ; For participant USA Canada : Must unsatisfactory response ( inadequate efficacy poor tolerability ) include 3 class analgesic medication ( acetaminophen/paracetamol , NSAIDs , opioids codeine codeine combination product ) Moderate severe pain functional impairment base NRS , WOMAC pain physical function subscales , PGA During treatment within 24 week last injection study drug : female childbearing potential , pregnant , breastfeeding , plan become pregnant , male , father child Increased risk osteonecrosis ( ON ) rapidly progressive osteoarthritis ( RPOA ) Unstable progressive neurologic disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>Pain</keyword>
	<keyword>Fulranumab</keyword>
	<keyword>JNJ-42160443</keyword>
	<keyword>Monotherapy</keyword>
	<keyword>Hip</keyword>
	<keyword>Knee</keyword>
	<keyword>Joint replacement surgery</keyword>
</DOC>